MedTrace Logo

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

NCT03333343 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 105

Last updated 2026-01-16

No results posted yet for this study

Summary

The study purpose is to evaluate the safety, tolerability, and preliminary efficacy of the addition of INC280, trametinib, ribociclib, gefitinib, or LXH254 to EGF816 in adult patients with advanced Epidermal growth factor receptor- mutant (EGFR-mutant) non-small cell lung cancer (NSCLC).

Conditions

  • EGFR-mutant Non-small Cell Lung Cancer

Interventions

DRUG

EGF816

Study Drug

DRUG

trametinib

Study Drug

DRUG

ribociclib

Study Drug

DRUG

LXH254

Study Drug

DRUG

INC280

Study Drug

DRUG

gefitinib

Study Drug

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
100 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-29
Primary Completion
2026-10-05
Completion
2026-10-05

Countries

  • Canada
  • Germany
  • Hong Kong
  • Italy
  • Singapore
  • Taiwan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03333343 on ClinicalTrials.gov